Начало › Множествен миелом › Юта › Salt Lake City
Клинични проучвания за Множествен миелом в Salt Lake City, UT
21 проучвания за Множествен миелом търсят участници в обекти в и около Salt Lake City (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Набиране на участнициФаза 3
- Research Site, Salt Lake City
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Набиране на участнициФаза 1/2
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 3
- Utah Cancer Specialists, Salt Lake City
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Набиране на участнициФаза 3
- LDS Hospital, Salt Lake City
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Набиране на участнициФаза 3
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Набиране на участнициФаза 2
- Intermountain Healthcare, Salt Lake City
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Набиране на участнициФаза 3
- Huntsman Cancer Institute, Salt Lake City
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Набиране на участнициФаза 2
- LDS Hospital, Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Набиране на участнициФаза 1/2
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Набиране на участнициФаза 2
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Набиране на участнициФаза 2
- Huntsman Cancer Institute, Salt Lake City
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Набиране на участнициФаза 1/2
- Research Site, Salt Lake City
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Набиране на участнициФаза 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Набиране на участнициФаза 1/2
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Набиране на участнициФаза 2
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Huntsman Cancer Center Institute University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Набиране на участнициФаза 1
- University of Utah, Salt Lake City
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Набиране на участнициФаза 1/2
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Набиране на участнициНаблюдателно проучване
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Набиране на участнициФаза 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Проучвания за Множествен миелом в други градове
- New York City, NY60 проучвания
- Boston, MA42 проучвания
- Atlanta, GA42 проучвания
- Houston, TX38 проучвания
- Durham, NC37 проучвания
- Nashville, TN32 проучвания
- Denver, CO27 проучвания
- Rochester, MN24 проучвания
- St. Louis, MO24 проучвания
- Columbus, OH24 проучвания
- Baldwin Park, CA23 проучвания
- Edison, NJ22 проучвания
Други проучвания в Salt Lake City
- Рак на белия дроб с недребноклетъчен тип31 проучвания
- Рак (всички видове)27 проучвания
- Рак на гърдата27 проучвания
- Колоректален рак22 проучвания
- Рак на белия дроб21 проучвания
- Меланом21 проучвания
- Метастатичен рак20 проучвания
- Рак на яйчниците19 проучвания
- Затлъстяване18 проучвания
- Остра миелоидна левкемия17 проучвания
- Сърдечна недостатъчност17 проучвания
- Рак на простатата15 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.